Volgens een onderzoek onder kankerpatiënten uit 2018 meldde één op de acht patiënten dat ze cannabis gebruikten om de symptomen van kanker te behandelen.
Pain, when used as an umbrella term, is more vast than the Pacific Ocean. Using CBD to treat pain can be effective only under the pretense that the type of pain is well-understood and properly diagnosed.
Chronic pain is the most common reason people give when they enroll in state-approved medical marijuana programs. That’s followed by stiffness from multiple sclerosis and chemotherapy-related nausea, according to an analysis of 15 states published Monday in the journal Health Affairs.
Parents of some autistic children have long reported that their kids calm down with cannabinoids, are better able to communicate, and can do more tasks by themselves. But because of the restrictions on cannabis research in the United States, there have been precious few real-world studies to confirm those anecdotal reports.
It’s safe to say 2018 was a monumental year for cannabis. Canada went legal, California tallied up recreational sales for the first time, and a new farm bill made the business of hemp legit in the eyes of the US government. If that wasn’t enough, two more states approved recreational sales while three approved medical sales.
The most exciting new frontier in cannabis research this year wasn’t any individual study or published report. It was a pair of developments (one in Canada, the other in the United States) that together promise to spur the research studies of the future on a scale never seen before, with a scope of inquiry that includes exploring potential benefits, rather than myopically focusing on potential harms.